Fortress Biotech (NASDAQ:FBIO) announced the creation of a new subsidiary called Aevitas Therapeutics, which will develop novel gene therapy approaches for complement-mediated diseases.
As quoted in the press release:
The proprietary technology, licensed from a leading university, uses adeno-associated virus (AAV)-based gene therapy to restore lasting production of functional complement regulatory proteins, providing a potentially curative treatment.
Irregularities in these proteins can play a vital role in an array of complement-mediated diseases, including atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH). Recent research has suggested that complement regulatory proteins could also play a key role in the pathogenesis of age-related macular degeneration.